In a recent post about contract manufacturing and IP, I discussed how Neuland doesn’t compete with clients in the generics space. A friend in Pharma subsequently asked me my thoughts…
As an advanced chemistry solutions provider, we are constantly asked by jobseekers which particular skills we are looking for in job candidates. Knowledge of complex chemistry? Demonstrable scientific problem-solving skills?…
You may have noticed we have a new style! Neuland recently unveiled our exciting new branding. It’s a refresh of Neuland’s look and a reminder of the values we cherish as…
Micronizing – and particularly nanosizing – active pharmaceutical ingredients (APIs) has become an integral part of the drug development & manufacturing process. And with a variety of techniques available to…
Intellectual property rights have always been integral to negotiations for pharmaceutical contract manufacturing services, but growing complexities surrounding global IP issues, complex science, inevitable process improvements, IT infrastructure & security,…
Related to our (persistent!) emphasis on regulatory excellence and complex chemistry capabilities, team members from Neuland Lab’s Analytical Research & Development Department at our R&D Centre developed and validated a…
Highly-Specialized Expertise Helps Pharma Focus on What They Do Best The discovery, manufacture and marketing of drugs is complex business indeed. So complex, in fact, that even the biggest of…
In February, FDA Commissioner Hamburg became the first-ever U.S. FDA commissioner to make an official visit to India. In a blog post back on February 11th – prior to her…
Bromination? Diazotization? Oxidation? Methylation? Niche chemistry is critical to the success of most therapeutics – whether it’s a cardiovascular, anti-fungal, anti-emetic, CNS, Parkinson’s or other drug. Pharmaceutical companies continue to…
At the heart of every drug lies one or more active pharmaceutical ingredients (APIs). While the phrase “regulatory affairs” typically conjures thoughts of FDA approvals of finished-dose drugs, regulatory matters…
